GOLD. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease. 2018 Report. https://goldcopd.org/wp-content/uploads/2017/11/GOLD-2018-v6.0-FINAL-revised-20-Nov_WMS.pdf. Accessed 28 Dec 2018.
Rajkumar P, Pattabi K, Vadivoo S, Bhome A, Brashier B, Bhattacharya P, et al. A cross-sectional study on prevalence of chronic obstructive pulmonary disease (COPD) in India: rationale and methods. BMJ Open. 2017;7(5):e015211.
Csikesz NG, Gartman EJ. New developments in the assessment of COPD: early diagnosis is key. Int J Chronic Obstruct Pulm Dis. 2014;9:277–86.
Welte T, Vogelmeier C, Papi A. COPD: early diagnosis and treatment to slow disease progression. Int J Clin Pract. 2015;69(3):336–49.
Jindal SK, Aggarwal AN, Gupta D, Agarwal R, Kumar R, Kaur T, et al. Indian study on epidemiology of asthma, respiratory symptoms and chronic bronchitis in adults (INSEARCH). Int J Tuberc Lung Dis. 2012;16(9):1270–7.
The burden of chronic respiratory diseases and their heterogeneity across the states of India: the Global Burden of Disease Study 1990–2016. Lancet Glob Health. 2018;6(12):e1363–74.
Lopez-Campos JL, Tan W, Soriano JB. Global burden of COPD. Respirology. 2016;21(1):14–23.
Hossain MM, Sultana A, Purohit N. Burden of chronic obstructive pulmonary disease in India: status, practices and prevention. Int J Pulm Res Sci. 2018;2(5).
Landis SH, Muellerova H, Mannino DM, Menezes AM, Han MK, van der Molen T, et al. Continuing to Confront COPD International Patient Survey: methods, COPD prevalence, and disease burden in 2012–2013. Int J Chron Obstruct Pulm Dis. 2014;9:597–611.
Stephen P, Mahalakshmy T, Manju R, Laksham KB, Subramani S, Panda K, et al. High prevalence of chronic respiratory symptoms among autorickshaw drivers of urban Puducherry, South India. Indian J Occup Environ Med. 2018;22(1):40–4.
Jones PW, Brusselle G, Dal Negro RW, Ferrerd M, Kardose P, Levy ML, et al. Health-related quality of life in patients by COPD severity within primary care in Europe. Respir Med. 2011;105(1):57–66.
WHO. Global Health Observatory (GHO) data. Mortality and global health estimates; 2016. http://who.int/gho/mortality_burden_disease/en/. Accessed 28 Dec 2018.
Salvi SS, Manap R, Beasley R. Understanding the true burden of COPD: the epidemiological challenges. Prim Care Respir J. 2012;21(3):249–51.
WHO. Noncommunicable Diseases (NCD) Country Profiles: India; 2016. https://www.who.int/nmh/countries/ind_en.pdf?ua=1. Accessed 28 Dec 2018.
Lopez AD, Shibuya K, Rao C, Mathers CD, Hansell AL, Held LS, et al. Chronic obstructive pulmonary disease: current burden and future projections. Eur Respir J. 2006;27(2):397–412.
Prescott E, Lange P, Vestbo J. Socioeconomic status, lung function and admission to hospital for COPD: results from the Copenhagen City Heart Study. Eur Respir J. 1999;13(5):1109–14.
Grigsby M, Siddharthan T, Chowdhury MA, Siddiquee A, Rubinstein A, Sobrino E, et al. Socioeconomic status and COPD among low- and middle-income countries. Int J Chron Obstruct Pulm Dis. 2016;11:2497–507.
Lange P, Marott JL, Vestbo J, Ingebrigtsen TS, Nordestgaard BG. Socioeconomic status and prognosis of COPD in Denmark. COPD. 2014;11(4):431–7.
Lawlor DA, Ebrahim S, Davey Smith G. Association between self-reported childhood socioeconomic position and adult lung function: findings from the British Women’s Heart and Health Study. Thorax. 2004;59(3):199–203.
Sehgal IS, Dhooria S, Agarwal R. Chronic obstructive pulmonary disease and malnutrition in developing countries. Curr Opin Pulm Med. 2017;23(2):139–48.
Ture DA, Demirci H, Sengoren Dikis O. The relationship between health literacy and disease specific costs in subjects with chronic obstructive pulmonary disease (COPD). The Aging Male (Epub 29 Sep 2018).
Murthy KJ, Sastry JG. Economic burden of chronic obstructive pulmonary disease. National Commission on Macroeconomics and Health background papers – burden of disease in India; 2005. p. 268–88. http://www.who.int/macrohealth/action/NCMH_Burden%20of%20disease_(29%20Sep%202005).pdf. Accessed 28 Dec 2018.
Kim C, Kim Y, Yang DW, Rhee CK, Kim SK, Hwang YI, et al. Direct and indirect costs of chronic obstructive pulmonary disease in Korea. Tuberc Respir Dis. 2019;82(1):27–34.
Mannino DM, Higuchi K, Yu TC, Zhou H, Li Y, Tian H, et al. Economic burden of COPD in the presence of comorbidities. Chest. 2015;148(1):138–50.
Chen X, Wang N, Chen Y, Xiao T, Fu C, Xu B. Costs of chronic obstructive pulmonary disease in urban areas of China: a cross-sectional study in four cities. Int J Chron Obstruct Pulm Dis. 2016;11:2625–32.
Lewis A, Torvinen S, Dekhuijzen PN, Chrystyn H, Watson AT, Blackney M, et al. The economic burden of asthma and chronic obstructive pulmonary disease and the impact of poor inhalation technique with commonly prescribed dry powder inhalers in three European countries. BMC Health Serv Res. 2016;16:251.
Wacker ME, Jorres RA, Schulz H, Heinrich J, Karrasch S, Karch A, et al. Direct and indirect costs of COPD and its comorbidities: results from the German COSYCONET study. Respir Med. 2016;111:39–46.
Dal Negro RW, Bonadiman L, Turco P, Tognella S, Iannazzo S. Costs of illness analysis in Italian patients with chronic obstructive pulmonary disease (COPD): an update. ClinicoEconomics Outcomes Res. 2015;7:153–9.
Darbà J, Ramírez G, García-Rivero JL, Mayoralas S, Pascual JF, Vargas D, et al. Estimating the economic consequences of an increased medication adherence due to a potential improvement in the inhaler technique with Spiromax® compared with Turbuhaler® in patients with moderate-to-severe chronic obstructive pulmonary disease in Spain. ClinicoEconomics Outcomes Res. 2017;9:127–37.
de Miguel Diez J, Carrasco Garrido P, Garcia Carballo M, Gilde Miguel A, Rejas Gutierrez J, Bellon Cano JM, et al. Determinants and predictors of the cost of COPD in primary care: a Spanish perspective. Int J Chron Obstruct Pulm Dis. 2008;3(4):701–12.
Patel KD, Lalwani T, Shah K. Economic burden in direct cost of chronic obstructive pulmonary disease at a tertiary care teaching hospital: a prospective observational cohort study. Indian J Pharm Pract. 2014;7(3):61–8.
Naveed A, Ali SA, Parveen A, Yousuf S, Ahmed A, Hashmi MA, et al. Prescription patterns and cost of illness in asthma and chronic obstructive pulmonary disease patients. Int J Acad Med. 2016;2:173–8.
Ministry of Health and Family Welfare, Government of India. National Health Accounts Estimates for India 2014–2015; 2017. https://mohfw.gov.in/sites/default/files/National%20Health%20Accounts%20Estimates%20Report%202014-15.pdf. Accessed 4 Jan 2019.
Lavorini F, Magnan A, Dubus JC, Voshaar T, Corbetta L, Broeders M, et al. Effect of incorrect use of dry powder inhalers on management of patients with asthma and COPD. Respir Med. 2008;102(4):593–604.
Chrystyn H, van der Palen J, Sharma R, Barnes N, Delafont B, Mahajan A, et al. Device errors in asthma and COPD: systematic literature review and meta-analysis. NPJ Prim Care Respir Med. 2017;27(1):22.
Sanchis J, Gich I, Pedersen S. Systematic review of errors in inhaler use: has patient technique improved over time? Chest. 2016;150(2):394–406.
Price D, Keininger DL, Viswanad B, Gasser M, Walda S, Gutzwiller FS. Factors associated with appropriate inhaler use in patients with COPD: lessons from the REAL survey. Int J Chron Obstruct Pulm Dis. 2018;13:695–702.
Sulaiman I, Cushen B, Greene G, Seheult J, Seow D, Rawat F, et al. Objective assessment of adherence to inhalers by patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2017;195(10):1333–43.
Vestbo J, Anderson JA, Calverley PMA, Celli B, Ferguson GT, Jenkins C, et al. Adherence to inhaled therapy, mortality and hospital admission in COPD. Thorax. 2009;64(11):939–43.
Carron T, Bridevaux PO, Lorvall K, Parmentier R, Moix JB, Beytrison V, et al. Feasibility, acceptability and effectiveness of integrated care for COPD patients: a mixed methods evaluation of a pilot community-based programme. Swiss Med Wkly. 2017;147:w14567.
Kruis AL, Smidt N, Assendelft WJ, Gussekloo J, Boland MR, Rutten-van Molken M, et al. Integrated disease management interventions for patients with chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2013;(10):CD009437.
Halpern MT, Stanford RH, Borker R. The burden of COPD in the U.S.A.: results from the Confronting COPD survey. Respir Med. 2003;97 Suppl C:S81–9.
Britton M. The burden of COPD in the U.K.: results from the Confronting COPD survey. Respir Med. 2003;97 Suppl C:S71–9.
Suhaj A, Manu MK, Unnikrishnan MK, Vijayanarayana K, Mallikarjuna Rao C. Effectiveness of clinical pharmacist intervention on health-related quality of life in chronic obstructive pulmonary disorder patients: a randomized controlled study. J Clin Pharm Ther. 2016;41(1):78–83.
Faheemuddin MD, Ramaiah B, Kiran SS, Kumari BS, Vijayalaxmi M. Evaluation of medication adherence in COPD patients and their drug utilisation pattern. Chron Obstruct Pulm Dis. 2016;1:17.
Abdulsalim S, Unnikrishnan MK, Manu MK, Alrasheedy AA, Godman B, Morisky DE. Structured pharmacist-led intervention programme to improve medication adherence in COPD patients: a randomized controlled study. Res Soc Admin Pharm. 2018;14(10):909–14.
Bourbeau J, Julien M, Maltais F, Rouleau M, Beaupre A, Begin R, et al. Reduction of hospital utilization in patients with chronic obstructive pulmonary disease: a disease-specific self-management intervention. Arch Intern Med. 2003;163(5):585–91.
Ghose D. India suffering critical shortage of doctors: NMC Bill may finally give rural poor access to affordable healthcare; 2018. https://www.firstpost.com/india/india-suffering-critical-shortage-of-doctors-nmc-bill-may-finally-give-rural-poor-access-to-affordable-healthcare-4285483.html. Accessed 4 Jan 2019.
Singh D, Bose A. Tackling doctors’ shortage. The Pioneer 2018. https://www.dailypioneer.com/2018/columnists/tackling-doctors-shortage.html. Accessed 4 Jan 2019.
Kumar R. The leadership crisis of medical profession in India: ongoing impact on the health system. J Fam Med Prim Care. 2015;4(2):159–61.
Ladhani S. COPD—an Indian perspective. J Lung Pulm Respir Res. 2016;3(1):24–5.
Cameron A, Ewen M, Ross-Degnan D, Ball D, Laing R. Medicine prices, availability, and affordability in 36 developing and middle-income countries: a secondary analysis. Lancet. 2009;373(9659):240–9.
Abdulsalim S, Unnikrishnan MK, Manu MK, Alrasheedy AA, Godman B, Morisky DE. Authors’ response to the comments to “Structured pharmacist-led intervention programme to improve medication adherence in COPD patients: a randomized controlled study”. Res Soc Admin Pharm. 2018;14(4):402–3.
Khdour MR, Kidney JC, Smyth BM, McElnay JC. Clinical pharmacy-led disease and medicine management programme for patients with COPD. Br J Clin Pharmacol. 2009;68(4):588–98.
Jarab AS, Alqudah SG, Khdour M, Shamssain M, Mukattash TL. Impact of pharmaceutical care on health outcomes in patients with COPD. Int J Clin Pharm. 2012;34(1):53–62.
Gallefoss F, Bakke PS. How does patient education and self-management among asthmatics and patients with chronic obstructive pulmonary disease affect medication? Am J Respir Crit Care Med. 1999;160(6):2000–5.
Gallefoss F. The effects of patient education in COPD in a 1-year follow-up randomised, controlled trial. Patient Educ Counsel. 2004;52(3):259–66.
Suhaj A, Unnikrishnan MK, Mohan MK, Kunhikkatta V, Rao CM. PRS2: effectiveness of clinical pharmacist intervention on direct medical cost in chronic obstructive pulmonary disorder patients—a randomized controlled study. Value Health. 2016;19:A807–918.
Sharma A, Ladd E, Unnikrishnan MK. Healthcare inequity and physician scarcity empowering non-physician healthcare. Econ Polit Wkly. 2013;48(13):112–7.
Garg S. Universal health coverage in India: newer innovations and the role of public health. Indian J Public Health. 2018;62:167–70.
Godman B, Oortwijn W, de Waure C, Mosca I, Puggina A, Specchia ML, et al. Links between pharmaceutical R&D models and access to affordable medicines. A study for the ENVI Committee. http://www.europarl.europa.eu/RegData/etudes/STUD/2016/587321/IPOL_STU(2016)587321_EN.pdf. Accessed 4 Jan 2019.
OECD. Health at a glance 2017. https://www.oecd-ilibrary.org/docserver/health_glance-2017-en.pdf?expires=1531413926&id=id&accname=guest&checksum=656327F799B10217DD2D80F463DAB8732017. Accessed 4 Jan 2019.
Triami Media BV. Historic inflation—CPI inflation year pages; 2017. www.inflation.eu.
Payscale. Average Clinical Pharmacist Salary. https://www.payscale.com/research/IN/Job=Clinical_Pharmacist/Salary. Accessed 20 Dec 2018.
Balkrishnan R, Christensen DB. Inhaled corticosteroid use and associated outcomes in elderly patients with moderate to severe chronic pulmonary disease. Clin Ther. 2000;22(4):452–69.
Suhaj A, Mohan MK, Mohapatra A, et al. Development and readability assessment of patient information leaflets for chronic obstructive pulmonary disease. Asian J Pharm Health Sci. 2015;5:1237–41.
Ravi Kumar BP, Dudala SR, Rao AR. Kuppuswamy’s socio-economic status scale: a revision of economic parameter for 2012. Int J Res Dev Health. 2013;1(1):2–4.
Hilleman DE, Dewan N, Malesker M, Friedman M. Pharmacoeconomic evaluation of COPD. Chest. 2000;118(5):1278–85.
Ofori-Asenso R, Agyeman AA. Irrational use of medicines—a summary of key concepts. Pharmacy. 2016;4:35.
Wright D, Twigg M, Barton G, Thornley T, Kerr C. An evaluation of a multi-site community pharmacy-based chronic obstructive pulmonary disease support service. Int J Pharm Pract. 2015;23(1):36–43.
Bourbeau J, Bartlett SJ. Patient adherence in COPD. Thorax. 2008;63(9):831–8.
Dal Negro RW, Tognella S, Tosatto R, Dionisi M, Turco P, Donner CF. Costs of chronic obstructive pulmonary disease (COPD) in Italy: the SIRIO study (Social Impact of Respiratory Integrated Outcomes). Respir Med. 2008;102(1):92–101.
Charles MS, Blanchette CM, Silver H, Lavallee D, Dalal AA, Mapel D. Adherence to controller therapy for chronic obstructive pulmonary disease: a review. Curr Med Res Opin. 2010;26(10):2421–9.
Cramer JA, Bradley-Kennedy C, Scalera A. Treatment persistence and compliance with medications for chronic obstructive pulmonary disease. Can Respir J. 2007;14(1):25–9.
Bender BG, Pedan A, Varasteh LT. Adherence and persistence with fluticasone propionate/salmeterol combination therapy. J Allergy Clin Immunol. 2006;118(4):899–904.
Brown P, Bluml BM, Kritzler R, Petryna M, Polley CM, Tietze KJ, et al. White paper on expanding the role of pharmacists in chronic obstructive pulmonary disease. J Am Pharm Assoc. 2011;51(2):203–11.
Bojanic L, Markovic-Pekovic V, Skrbic R, Stojakovic N, Ethermanovic M, Bojanic J, et al. Recent initiatives in the Republic of Srpska to enhance appropriate use of antibiotics in ambulatory care; their influence and implications. Front Pharmacol. 2018;9:442.
Mohan MK, Vineetha R. Medical insurance: promoting unethical practices? Indian J Med Ethics. 2011;8(4):261.
Gustafsson LL, Wettermark B, Godman B, Andersen-Karlsson E, Bergman U, Hasselstrom J, et al. The ‘wise list’—a comprehensive concept to select, communicate and achieve adherence to recommendations of essential drugs in ambulatory care in Stockholm. Basic Clin Pharmacol Toxicol. 2011;108(4):224–33.
Meyer JC, Schellack N, Stokes J, Lancaster R, Zeeman H, Defty D, et al. Ongoing initiatives to improve the quality and efficiency of medicine use within the public healthcare system in South Africa: a preliminary study. Front Pharmacol. 2017;8:751.
Niaz Q, Godman B, Massele A, Campbell S, Kurdi A, Kagoya HR, et al. Validity of World Health Organisation prescribing indicators in Namibia’s primary healthcare: findings and implications. Int J Qual Health Care. 2019;31(5):338–45.
Cameron A, Mantel-Teeuwisse AK, Leufkens HG, Laing RO. Switching from originator brand medicines to generic equivalents in selected developing countries: how much could be saved? Value Health. 2012;15(5):664–73.
Alrasheedy AA, Hassali MA, Wong ZY, Saleem F. Pharmacist-managed medication therapy adherence clinics: the Malaysian experience. Res Soc Admin Pharm. 2017;13(4):885–6.
Cheng HM, Liu WC, Chua G, Liew CF, Li W, Choo W, et al. Impact of a pharmacy-led smoking cessation clinic in a dermatology centre. Singapore Med J. 2019;60(1):31–3.
Bock BC, Hudmon KS, Christian J, Graham AL, Bock FR. A tailored intervention to support pharmacy-based counseling for smoking cessation. Nicotine Tob Res. 2010;12(3):217–25.
Twigg MJ, Wright DJ. Community pharmacy COPD services: what do researchers and policy makers need to know? Integr Pharm Res Pract. 2017;6:53–9.